Mink therapeutics to participate in 4th annual evercore isi healthconx conference

New york, nov. 17, 2021 (globe newswire) -- mink therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases today announced that dr. jennifer buell, president and ceo of mink, will participate in a fireside chat hosted by evercore on december 1st, 2021, at 8:25 am et.
INKT Ratings Summary
INKT Quant Ranking